{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:27:38Z","timestamp":1792819658852,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bbadis.2022.166556","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T03:28:34Z","timestamp":1663903714000},"page":"166556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk\/-Egr-1 signaling and Tgf\u03b21\/Smad pathway in mice"],"prefix":"10.1016","volume":"1868","author":[{"given":"Huiwen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongtao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijian","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bbadis.2022.166556_bb0005","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.mayocp.2020.01.015","article-title":"Cholestatic liver diseases: a primer for generalists and subspecialists","volume":"95","author":"Hilscher","year":"2020","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.bbadis.2022.166556_bb0010","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hep.28965","article-title":"The ascending pathophysiology of cholestatic liver disease","volume":"65","author":"Jansen","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bbadis.2022.166556_bb0015","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00281-009-0164-5","article-title":"Primary biliary cirrhosis","volume":"31","author":"Hohenester","year":"2009","journal-title":"Semin. Immunopathol."},{"issue":"1","key":"10.1016\/j.bbadis.2022.166556_bb0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cld.2007.11.013","article-title":"Medical treatment of cholestatic liver disease","volume":"12","author":"Paumgartner","year":"2008","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.bbadis.2022.166556_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2017.06.020","article-title":"Primary biliary cholangitis: old and novel therapy","volume":"47","author":"Floreani","year":"2018","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.bbadis.2022.166556_bb0030","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bbadis.2022.166556_bb0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cld.2015.08.006","article-title":"Novel therapies on primary biliary cirrhosis","volume":"20","author":"Czul","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"3","key":"10.1016\/j.bbadis.2022.166556_bb0040","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.27074","article-title":"Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis","volume":"60","author":"Wunsch","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bbadis.2022.166556_bb0045","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/molecules17010884","article-title":"Design, synthesis and antifibrotic activities of carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1H) pyridones","volume":"17","author":"Lou","year":"2012","journal-title":"Molecules"},{"issue":"1\u20132","key":"10.1016\/j.bbadis.2022.166556_bb0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000329419","article-title":"Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db\/db mice","volume":"88","author":"Wang","year":"2011","journal-title":"Pharmacology"},{"issue":"12","key":"10.1016\/j.bbadis.2022.166556_bb0055","doi-asserted-by":"crossref","first-page":"14325","DOI":"10.1096\/fj.201901468RR","article-title":"Fluorofenidone protects against acute kidney injury","volume":"33","author":"Jiang","year":"2019","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.bbadis.2022.166556_bb0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/SHK.0000000000000273","article-title":"Fluorofenidone attenuates TGF-beta1-induced lung fibroblast activation via restoring the expression of caveolin-1","volume":"43","author":"Liu","year":"2015","journal-title":"Shock"},{"key":"10.1016\/j.bbadis.2022.166556_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.772031","article-title":"Protective effect of fluorofenidone against acute lung injury through suppressing the MAPK\/NF-kappaB pathway","volume":"12","author":"Lv","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbadis.2022.166556_bb0070","first-page":"452","article-title":"Fluorofenidone inhibits transforming growth factor-beta1-induced cardiac myofibroblast differentiation","volume":"67","author":"Chen","year":"2012","journal-title":"Pharmazie"},{"issue":"7","key":"10.1016\/j.bbadis.2022.166556_bb0075","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002402R","article-title":"Fluorofenidone protects liver against inflammation and fibrosis by blocking the activation of NF-kappaB pathway","volume":"35","author":"Tu","year":"2021","journal-title":"FASEB J."},{"issue":"11","key":"10.1016\/j.bbadis.2022.166556_bb0080","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/jcmm.12898","article-title":"Fluorofenidone attenuates pulmonary inflammation and fibrosis via inhibiting the activation of NALP3 inflammasome and IL-1beta\/IL-1R1\/MyD88\/NF-kappaB pathway","volume":"20","author":"Song","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbadis.2022.166556_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.534775","article-title":"Fluorofenidone alleviates renal fibrosis by inhibiting necroptosis through RIPK3\/MLKL pathway","volume":"11","author":"Dai","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbadis.2022.166556_bb0090","doi-asserted-by":"crossref","first-page":"G253","DOI":"10.1152\/ajpgi.00471.2012","article-title":"Fluorofenidone attenuates hepatic fibrosis by suppressing the proliferation and activation of hepatic stellate cells","volume":"306","author":"Peng","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbadis.2022.166556_bb0095","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.930166","article-title":"Effect of fluorofenidone against paraquat-induced pulmonary fibrosis based on metabolomics and network pharmacology","volume":"27","author":"Jiang","year":"2021","journal-title":"Med. Sci. Monit."},{"issue":"11","key":"10.1016\/j.bbadis.2022.166556_bb0100","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20198772","article-title":"Fluorofenidone inhibits apoptosis of renal tubular epithelial cells in rats with renal interstitial fibrosis","volume":"52","author":"Yang","year":"2019","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.bbadis.2022.166556_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2017.11.024","article-title":"Effects of pirfenidone in acute and sub-chronic liver fibrosis, and an initiation-promotion cancer model in the mouse","volume":"339","author":"Seniutkin","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"11","key":"10.1016\/j.bbadis.2022.166556_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.594","article-title":"A novel role for interleukin 32 in cholestasis","volume":"11","author":"Zhang","year":"2021","journal-title":"Clin Transl Med"},{"issue":"1","key":"10.1016\/j.bbadis.2022.166556_bb0115","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1038\/s41598-018-24825-x","article-title":"Pivotal roles of Kupffer cells in the progression and regression of DDC-induced chronic cholangiopathy","volume":"8","author":"Jemail","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bbadis.2022.166556_bb0120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.bbadis.2022.166556_bb0125","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1158\/0008-5472.CAN-05-4609","article-title":"Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice","volume":"66","author":"Farazi","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2022.166556_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.669037","article-title":"Adipose stromal cell-secretome counteracts profibrotic signals from IPF lung matrices","volume":"12","author":"Vasse","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbadis.2022.166556_bb0135","first-page":"L877","article-title":"Use of proper statistical techniques for research studies with small samples","volume":"313","author":"Morgan","year":"2017","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.bbadis.2022.166556_bb0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mam.2017.06.001","article-title":"Mechanisms of bile acid mediated inflammation in the liver","volume":"56","author":"Li","year":"2017","journal-title":"Mol. Asp. Med."},{"issue":"6","key":"10.1016\/j.bbadis.2022.166556_bb0145","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.bbadis.2022.166556_bb0150","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1042\/CS20181123","article-title":"Immunological abnormalities in patients with primary biliary cholangitis","volume":"133","author":"Ma","year":"2019","journal-title":"Clin. Sci. (Lond.)"},{"issue":"16","key":"10.1016\/j.bbadis.2022.166556_bb0155","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/febs.14466","article-title":"A guide to chemokines and their receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"FEBS J."},{"issue":"2","key":"10.1016\/j.bbadis.2022.166556_bb0160","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/toxsci\/kfj111","article-title":"Early growth response factor-1 is critical for cholestatic liver injury","volume":"90","author":"Kim","year":"2006","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.bbadis.2022.166556_bb0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.taap.2009.11.013","article-title":"Upregulation of early growth response factor-1 by bile acids requires mitogen-activated protein kinase signaling","volume":"243","author":"Allen","year":"2010","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bbadis.2022.166556_bb0170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu. Rev. Biochem."},{"issue":"6","key":"10.1016\/j.bbadis.2022.166556_bb0175","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bbadis.2022.166556_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113630","article-title":"Nuclear receptor metabolism of bile acids and xenobiotics: a coordinated detoxification system with impact on health and diseases","volume":"19","author":"Garcia","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"10308","key":"10.1016\/j.bbadis.2022.166556_bb0185","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gines","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bbadis.2022.166556_bb0190","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2022.166556_bb0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol. Asp. Med."},{"issue":"5","key":"10.1016\/j.bbadis.2022.166556_bb0200","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.bbadis.2022.166556_bb0205","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00018-015-1861-y","article-title":"Pathological implications of cadherin zonation in mouse liver","volume":"72","author":"Hempel","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"issue":"4 Pt B","key":"10.1016\/j.bbadis.2022.166556_bb0210","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.bbadis.2017.06.027","article-title":"Animal models of biliary injury and altered bile acid metabolism","volume":"1864","author":"Mariotti","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"2","key":"10.1016\/j.bbadis.2022.166556_bb0215","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2353\/ajpath.2007.061133","article-title":"A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis","volume":"171","author":"Fickert","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"10139","key":"10.1016\/j.bbadis.2022.166556_bb0220","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerosing cholangitis","volume":"391","author":"Dyson","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bbadis.2022.166556_bb0225","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2013.06.052","article-title":"Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management","volume":"145","author":"Eaton","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2022.166556_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.152948","article-title":"Protective effect of herbal medicine Huangqi decoction against chronic cholestatic liver injury by inhibiting bile acid-stimulated inflammation in DDC-induced mice","volume":"62","author":"Li","year":"2019","journal-title":"Phytomedicine"},{"issue":"6","key":"10.1016\/j.bbadis.2022.166556_bb0235","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0168-8278(02)00272-6","article-title":"Pirfenidone effectively reverses experimental liver fibrosis","volume":"37","author":"Garcia","year":"2002","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.bbadis.2022.166556_bb0240","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1053\/j.gastro.2009.12.055","article-title":"Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress","volume":"138","author":"Hanada","year":"2010","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bbadis.2022.166556_bb0245","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1124\/dmd.105.009035","article-title":"Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine","volume":"34","author":"Martignoni","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bbadis.2022.166556_bb0250","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3109\/03602532.2011.597401","article-title":"In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences","volume":"43","author":"Komura","year":"2011","journal-title":"Drug Metab. Rev."},{"issue":"5","key":"10.1016\/j.bbadis.2022.166556_bb0255","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90780","article-title":"Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response","volume":"2","author":"Cai","year":"2017","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.bbadis.2022.166556_bb0260","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/liv.12048","article-title":"Contrasting responses of Kupffer cells and inflammatory mononuclear phagocytes to biliary obstruction in a mouse model of cholestatic liver injury","volume":"33","author":"Duwaerts","year":"2013","journal-title":"Liver Int."},{"issue":"5","key":"10.1016\/j.bbadis.2022.166556_bb0265","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ajpath.2013.07.019","article-title":"IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis","volume":"183","author":"O\u2019Brien","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.bbadis.2022.166556_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188736","article-title":"E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers","volume":"1877","author":"Park","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"10","key":"10.1016\/j.bbadis.2022.166556_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111242","article-title":"Fluorofenidone offers improved renoprotection at early interventions during the course of diabetic nephropathy in db\/db mice via multiple pathways","volume":"9","author":"Xiong","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bbadis.2022.166556_bb0280","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MAJ.0000000000000501","article-title":"The protective mechanism of fluorofenidone in renal interstitial inflammation and fibrosis","volume":"350","author":"Tang","year":"2015","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.bbadis.2022.166556_bb0285","doi-asserted-by":"crossref","first-page":"31494","DOI":"10.1002\/hep.31494","article-title":"Bidirectional role of NLRP3 during acute and chronic cholestatic liver injury","volume":"73","author":"Frissen","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bbadis.2022.166556_bb0290","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/nep.13062","article-title":"Fluorofenidone attenuates interleukin-1\u03b2 production by interacting with NLRP3 inflammasome in unilateral ureteral obstruction","volume":"23","author":"Zheng","year":"2018","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"10.1016\/j.bbadis.2022.166556_bb0295","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.intimp.2015.05.008","article-title":"Fluorofenidone inhibits macrophage IL-1\u03b2 production by suppressing inflammasome activity","volume":"27","author":"Lu","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.bbadis.2022.166556_bb0300","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cmet.2017.03.007","article-title":"Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis","volume":"25","author":"Hao","year":"2017","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.bbadis.2022.166556_bb0305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.livres.2020.05.001","article-title":"Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis","volume":"4","author":"Chiang","year":"2020","journal-title":"Liver Res"},{"issue":"19","key":"10.1016\/j.bbadis.2022.166556_bb0310","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbadis.2022.166556_bb0315","first-page":"41","article-title":"Fluorofenidone affects hepatic stellate cell activation in hepatic fibrosis by targeting the TGF-beta1\/Smad and MAPK signaling pathways","volume":"18","author":"Peng","year":"2019","journal-title":"Exp Ther Med"},{"issue":"7","key":"10.1016\/j.bbadis.2022.166556_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00498254.2020.1820626","article-title":"In vitro inhibition and induction of human liver cytochrome P450 enzymes by a novel anti-fibrotic drug fluorofenidone","volume":"51","author":"Li","year":"2021","journal-title":"Xenobiotica"},{"issue":"9","key":"10.1016\/j.bbadis.2022.166556_bb0325","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0090-9556(24)02975-1","article-title":"CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes","volume":"32","author":"Ram\u00edrez","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.bbadis.2022.166556_bb0330","first-page":"289","article-title":"Norpethidine accumulation and generalized seizure during pethidine patient-controlled analgesia","volume":"27","author":"McHugh","year":"1999","journal-title":"Anaesth. Intensive Care"},{"issue":"5","key":"10.1016\/j.bbadis.2022.166556_bb0335","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/bja\/71.5.738","article-title":"Norpethidine toxicity and patient controlled analgesia","volume":"71","author":"Stone","year":"1993","journal-title":"Br. J. Anaesth."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443922002277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443922002277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:15:21Z","timestamp":1760418921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443922002277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0925443922002277"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2022.166556","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk\/-Egr-1 signaling and Tgf\u03b21\/Smad pathway in mice","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2022.166556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"166556"}}